Lundbeck invests in Ossianix for neurological drugs

01/3/2012 | Reuters

Ossianix received a convertible promissory note from H. Lundbeck to help it develop biopharmaceutical agents for the central nervous system. Lundbeck has negotiation rights for certain medicines and technology resulting from the project. Separately, Lundbeck rolled out epilepsy treatment Onfi in the U.S.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC